Executive changes at Planet Biopharmaceuticals
This article was originally published in Scrip
Planet Biopharmaceuticals, a privately-held speciality pharmaceutical company focused on providing products for allergy and asthma sufferers, has appointed Dr Theron Odlaug executive chairman and CEO effective 29 August, replacing William Goldberg who has joined MediMedia USA as CEO. Mr Goldberg will remain on Planet's board of directors. Dr Odlaug most recently served as president and CEO of CyDex Pharmacueticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.